Last updated: February 13, 2026
Overview of NDC 49483-0242
The drug identified by NDC 49483-0242 corresponds to Blenrep (belantamab mafodotin-blmf), a monoclonal antibody-drug conjugate marketed by GlaxoSmithKline for treatment of relapsed or refractory multiple myeloma. Approved by the FDA in August 2020 under FARGO (Blenrep) label, it is used in adult patients who have received at least four prior therapies.
Market Landscape
Target Population:
Approximately 30,000 multiple myeloma patients in the U.S. meet the criteria for Blenrep therapy, based on epidemiological data. The drug is indicated as a third- or later-line therapy, limiting its ~market size~ but targeting a high-value patient subset.
Competitive Environment:
Blenrep competes primarily with:
- Selinexor (Xpovio): A selective inhibitor of nuclear export.
- Carfilzomib (Kyprolis) and Pomalidomide (Pomalyst): Proteasome inhibitors and immunomodulators, respectively.
- Upcoming therapies: GSK-initiated trials for potential combination regimens or next-generation antibody conjugates.
Market Penetration:
Despite regulatory approval, initial market penetration was slow in 2020-2021 due to:
- Administration challenges: Ocular side effects requiring monitoring.
- Treatment complexity: Prior chemotherapy regimens among patients.
- Pricing hesitations: Payer and provider adoption lag.
By 2022, market share increased as safety profiles established and treatment protocols adapted.
Pricing Insights
Current Pricing (2023):
The Wholesale Acquisition Cost (WAC) for Blenrep is approximately $17,400 per vial. Patients typically receive three vials per treatment cycle, equaling about $52,200 per cycle.
Cost Calculations:
- Per cycle: $52,200
- Annual treatment cost (assuming four cycles): about $208,800
Pricing Strategy Factors:
- Orphan drug status provides marketing exclusivity until 2030.
- Pricing tiers: Discounted prices often apply via payers and pharmacy benefit managers.
- Reimbursements: Reimbursement rates align with WAC, less negotiated discounts.
Revenue Projections
Market Penetration Estimates:
- 2023: 10% market share within eligible patient population.
- 2024: 15% as physician familiarity and safety monitoring improve.
- 2025: 20%-25% with increased indication awareness and supportive therapy protocols.
Revenue Forecast:
| Year |
Estimated Patients Treated |
Market Penetration |
Annual Revenue (USD) |
| 2023 |
3,000 |
10% |
~$625 million |
| 2024 |
4,500 |
15% |
~$938 million |
| 2025 |
6,000 |
20%-25% |
~$1.25–1.56 billion |
(Assumption: steady increase in treatment rates and reimbursement coverage)
Pricing Outlook:
- Slight reductions in WAC through negotiations may occur, potentially reducing per-cycle cost by 5–10% by 2025.
- Introduction of biosimilars is unlikely before 2030 due to patent protection and orphan drug status.
External Factors Influencing Price and Market
- FDA approvals: Additional indications could expand market size.
- Reimbursement policies: CMS and private payers’ coverage decisions affect uptake.
- Competitive innovations: New therapies could pressure prices downward.
- Manufacturing costs: Stability in raw material sourcing influences production pricing.
Key Takeaways
- NDC 49483-0242 (Blenrep) has a targeted patient population with limited overall market size but high per-treatment revenue potential.
- The drug's current price remains steady at approximately $17,400 per vial, with treatment costs around $52,200 per cycle.
- Revenue projections suggest a potential for over $1 billion annually by 2025, contingent on adoption rates and competitive dynamics.
- Market growth hinges on drug safety profile management, payer acceptance, and potential regulatory expansions.
- Price discounts and biosimilar entry are unlikely before the late 2020s, maintaining current high price levels.
FAQs
1. How does the current price of Blenrep compare to similar therapies?
Blenrep’s approximately $17,400 per vial aligns with other monoclonal antibody conjugates, which typically range from $15,000 to $20,000 per dose, depending on complexity and exclusivity.
2. What factors could influence a decrease in Blenrep’s price?
Introduction of biosimilars after patent expiry, streamlining manufacturing costs, and increased competitive therapies could reduce list prices or negotiated reimbursement rates.
3. Are there ongoing studies that could expand the drug’s indications?
Yes, GSK is investigating Blenrep in combination regimens and earlier lines of therapy, which could broaden its market and justify price adjustments.
4. What is the impact of ocular side effects on market adoption?
Ocular toxicity requires monitoring and management, which can delay adoption, but improved safety protocols have mitigated this impact.
5. How do payer policies affect potential revenue?
Payer coverage determines access, with insurers potentially negotiating discounts, formulary restrictions, or step therapy protocols that influence actual revenue realizations.
References
[1] U.S. Food and Drug Administration. FDA approval for belantamab mafodotin-blmf (Blenrep). August 2020.
[2] IQVIA. National Prescription Audit, 2023.
[3] GlaxoSmithKline. Blenrep prescribing information. 2020.
[4] Market data and epidemiology reports from American Cancer Society, 2022.
